



1

---

---

---


---

---

---

---

---



2

---

---

---


---

---

---

---

---



3

---

---

---


---

---

---

---

---



4

---

---

---

---

---


---

---

---

---

---



5

---

---

---

---

---


---

---

---

---

---



6

---

---

---

---

---

---


---

---

---

---

### Hallmarks of Alzheimer's Disease



ALZHEIMER'S ASSOCIATION

7

---

---

---

---


---

---

---

---

### Alzheimer's Disease is a Continuum



ALZHEIMER'S ASSOCIATION

8

---

---

---

---


---

---

---

---

### What May Impact Risk of Cognitive Decline or Dementia



ALZHEIMER'S ASSOCIATION

9

---

---

---

---

---

---

---

---

 Exciting Time in Research



ALZHEIMER'S ASSOCIATION

10

---

---

---

---

---

---

---

---

---

---

**World's Largest Nonprofit Funder of Alzheimer's & All Dementia Research**

Find GRANT info at [alz.org/grants](https://alz.org/grants)

-  **\$405M** currently active
-  **1100+** projects
-  **56** countries

ALZHEIMER'S ASSOCIATION

11

---

---

---

---

---

---

---

---

---

---

**We Advocate**

**Alzheimer's and Related Dementia Research Funding at the NIH**




Today, Alzheimer's and dementia research funding is more than \$3.7 billion annually. Since the passage of the Alzheimer's Accountability Act, Congress has increased Alzheimer's and dementia research funding more than seven-fold.

Source: NIH (<https://report.nih.gov/funding/categorical-spending/>) with the 2023 figure reflecting NIH's estimated 2023 funding plus the additional increase of \$26M appropriated through the FY2023 omnibus.

ALZHEIMER'S ASSOCIATION

12

---

---

---

---

---

---

---

---

---

---

### RESEARCH IN YOUR COMMUNITY

We have played a role in nearly every significant development in Alzheimer's science to date

**Wisconsin**



**ISTAART**  
104 Members

**Grant Funding**



Total awards: 32  
Year: 1993-2023  
Active awards: 8



Total amount: \$ 4.8 M  
Active amount: \$ 1.6 M

**Grant Reviewers**



Reviewers: 54  
Critiques: 470

**Funded Institutions**



University of Wisconsin-Madison,  
Medical College of Wisconsin,  
University of Wisconsin-Milwaukee,

ALZHEIMER'S ASSOCIATION

---

---

---

---

---

---


---

---

13


### Ultra-Processed Food & Dementia Risk: What You Eat May Change Your Brain

**20%**  
Of caloric intake



Consuming more than 20% of daily caloric intake in ultra-processed food is associated with a 28% faster decline in global cognitive scores

**28%**  
Faster decline in cognition



Ultra-processed foods make up more than 50% of American diets – a troubling statistic given the effect on cognitive decline

**Key Takeaway:** It is never too late to incorporate one or two healthful actions into your lifestyle that may help protect against cognitive decline as you age

ALZHEIMER'S ASSOCIATION

---

---

---

---

---


---

---

---

14

### EXERT Study Findings: Physical Activity May Stall Cognitive Decline



EXERT Study is the longest-ever Phase 3 study of exercise in older adults with Mild Cognitive Impairment (MCI)

The study was conducted during the COVID-19 pandemic and 80% of study participants complied with their exercise regimen

After 12 months, study participants with MCI in both aerobic intervention and stretching arm showed no cognitive decline

**Key Takeaway:** Regular aerobic exercise or stretching and balance may still stall cognitive decline in sedentary adults with MCI

ALZHEIMER'S ASSOCIATION

---

---

---

---


---


---

---

---

15

 Early Detection and Diagnosis



ALZHEIMER'S ASSOCIATION

16

---

---

---


---

---

---

---

---



**An early diagnosis can have emotional, social and medical benefits**

- Understand symptoms
- Explore treatment options
- Improve health outcomes
- Prevent complications
- Make legal and financial decisions
- Access care services
- Participate in clinical trials
- Effectively manage the cost of care

ALZHEIMER'S ASSOCIATION

17

---

---

---

---

---

---

---

---


**Alzheimer's and Dementia Care ECHO: Primary Care**

➤ **Twelve, bi-weekly 1-hour sessions** Case-based, interactive learning sessions

- Short didactic lessons on best practice care and group consultation on de-identified patients from community clinics

➤ **Benefits**

- guidance and mentoring from nationally recognized experts and peers
- community of learners
- no cost CME
- increased confidence and knowledge



ALZHEIMER'S ASSOCIATION

18

---

---

---

---


---

---

---

---

### New Era of Diagnostics: Cerebrospinal Fluid (CSF) & Blood Tests



- Global race to uncover and develop fluid based biomarkers for Alzheimer's and other dementia
- More than beta amyloid and tau; emerging markers of cell death, inflammation and vascular related changes are being developed
- Fluid tests are valuable tools to help streamline clinical trial enrollment
- Current available fluid tests predict the presence of Alzheimer's amyloid brain plaques
  - 4 FDA approved amyloid CSF test on market for Alzheimer's
  - Several emerging amyloid blood tests on market for Alzheimer's
  - Should be prescribed by healthcare providers to individuals with a cognitive concern.
- However, additional data are needed before blood tests can be used as a stand-alone test for diagnosis, and before considering broad use in primary care settings.

ALZHEIMER'S ASSOCIATION

19

---

---

---

---

---

---


---

---

---

---

### Progress Towards Risk Reduction and More Effective Treatments



ALZHEIMER'S ASSOCIATION

20

---

---

---

---

---

---

---

---

---

---

### FDA Approved Therapies for Alzheimer's Disease

Year	Drug	Targeted Symptom
1906	First description of disease	-
1996	Donepezil (Aricept)	Treats Symptoms
2000	Rivastigmine (Exelon)	Treats Symptoms
2001	Galantamine (Razadyne)	Treats Symptoms
2003	Memantine (Namenda)	Treats Symptoms
2014	Memantine + Donepezil (Namzaric)	Treats Symptoms
2020	Suvorexant (Belsomra)	Treats Symptoms (Insomnia)
2021	Aducanumab (Aduhelm)	Slows Disease Progression
2023	Lecanemab (Leqembi)	Slows Disease Progression
2023	Brexipiprazole (Rexulti)	Treats Symptoms (Agitation)

ALZHEIMER'S ASSOCIATION

\* Suvorexant approved for insomnia not AD but safe and effective in AD population

21

---

---

---

---

---

---

---

---

---

---

### A New Phase of Treatment

Today, Over 140 Unique Therapies Being Tested in Clinical Trials that Target Multiple Aspects of Alzheimer's Biology

Year	Target	Drug
2021	Targets amyloid	Aducanumab (Aduhelm™)
2023	Targets amyloid	Lecanemab (Leqembi™)
2024	Targets amyloid	Donanemab (FDA review pending Q1 2024)

ALZHEIMER'S ASSOCIATION

22

---

---

---

---

---

---

---

---

### How to Get Involved in Research

**Over 370,000 Users**  
**750+ Clinical Studies at Locations around the world**  
[alz.org/trialmatch](http://alz.org/trialmatch)

TrialMatch is a free clinical studies matching service designed to provide a customized list of potential study matches to each user.

Count	Category
641	Alzheimer's disease
278	Mild Cognitive Impairment
21	Vascular Dementia
88	Other Dementia

ALZHEIMER'S ASSOCIATION

23

---

---

---

---

---

---

---

---

### Alzheimer's Association Research Resources

- Association's Website | [alz.org](http://alz.org)
- Research at the Association | [alz.org/research](http://alz.org/research)
- Join a Clinical Trial | [alz.org/trialmatch](http://alz.org/trialmatch)
- Contact the 24/7 helpline | 800-272-3900

ALZHEIMER'S ASSOCIATION

24

---

---

---

---

---

---

---

---





25

---

---

---

---

---

---

---

---